AB-FUBINACA

Buy AB-FUBINACA Online

AB-FUBINACA, a synthetic cannabinoid, has garnered attention as a potent agonist for cannabinoid receptors. Its unique structure and pharmacological profile set it apart in the realm of designer drugs. Here, we delve into the intricacies of AB-FUBINACA, exploring its binding affinity, chemical properties, and regulatory status.

Chemical Composition: AB-FUBINACA, scientifically known as N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide, belongs to the synthetic indazole cannabinoid class. The indazole core, with a 4-fluorophenyl group as a substitute, forms the backbone of this compound. Notably, it exhibits a unique binding arrangement, with a methyl group at R1, a carboxamide group at R3, and a terminal amine of carboxamide bonding to a substitute propyl chain.

Pharmacological Insights: AB FUBINACA manifests its effects through full agonism at both CB1 and CB2 cannabinoid receptors, displaying some selectivity for CB2. While the exact mechanisms leading to the cannabinoid high experience remain elusive, the compound’s structural similarities to other cannabinoids, particularly Δ9-THC, hint at a comparable binding profile.

Administration and Solubility: Synthetic cannabinoids like AB-FUBINACA are commonly consumed through smoking or vaporization for rapid onset and offset of effects. Interestingly, when dissolved in lipids, FUBINACA becomes orally active, prolonging its duration. Notably, it remains insoluble in water but exhibits solubility in ethanol and lipids.

Regulatory Landscape: Despite its potential therapeutic applications, AB-FUBINACA has faced regulatory scrutiny. Certain US states have implemented controls on its distribution and use. The compound’s intricate chemical structure and pharmacological effects contribute to ongoing research aimed at understanding its full range of properties.

Origins and Discovery: Originally developed by Pfizer in 2009 as an analgesic medication, AB-FUBINACA took an unexpected turn when it surfaced as an ingredient in synthetic cannabis blends in Japan in 2012. This unintended diversion highlights the challenges associated with synthetic cannabinoids and their unpredictable pathways in the illicit drug market.

Safety Considerations: Chronic abuse of synthetic cannabinoids, including AB-FUBINACA, has been linked to adverse effects and toxicity. The compound’s journey from a pharmaceutical prospect to a recreational substance underscores the need for comprehensive safety assessments and regulatory controls.

Buy AB-FUBINACA Online: AB-FUBINACA, with its intricate molecular structure and pharmacological actions, stands as a testament to the evolving landscape of synthetic cannabinoids. As researchers continue to unravel its mysteries, the compound’s role in both therapeutic and recreational contexts remains a subject of scientific exploration and regulatory vigilance.

Other Chems:  U-47700